Liminatus Pharma, Inc.
LIMN
$14.43
$1.6312.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Net Income | -50.00% | 70.30% | 99.99% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | -- | ||
| Change in Net Operating Assets | 50.00% | -80.53% | -99.86% | ||
| Cash from Operations | -- | 55.80% | 100.00% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -17.27% | -- | ||
| Cash from Investing | -- | -17.27% | -- | ||
| Total Debt Issued | -- | -50.00% | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -- | -41.67% | 138.80% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -97.82% | 91.61% | ||